目的 探究舒肝解郁胶囊联合阿戈美拉汀治疗脑梗死后抑郁的临床疗效。方法 选取2015年1月-2016年12月哈励逊国际和平医院收治的脑梗死后抑郁患者68例，随机分为对照组和治疗组，每组各34例。对照组患者口服阿戈美拉汀片，25~50 mg/d。治疗组患者在对照组的基础上口服舒肝解郁胶囊，2粒/次，2次/d。两组患者均连续治疗8周。评价两组患者临床疗效，同时比较治疗前后两组患者汉密尔顿抑郁量表（HAMD）和焦虑量表（HAMA）评分以及不良反应情况。结果 治疗后，对照组和治疗组总有效率分别为79.41%、91.18%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者HAMD和HAMA评分均显著降低，同组比较差异具有统计学意义（P<0.05）；且治疗组患者HAMD和HAMA评分低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗组患者不良反应的发生率为20.58%，显著低于对照组患者的29.41%，两组比较差异具有统计学意义（P<0.05）。结论 舒肝解郁胶囊联合阿戈美拉汀能够有效的消除脑梗死患者的负面情绪，提高患者的生活质量，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Shugan Jieyu Capsules combined with aggameline in treatment of depression after cerebral infarction. Methods Patients (68 cases) with depression after cerebral infarction in Harrison International Peace Hospital from January 2015 to December 2016 were randomly divided into control and treatment groups, and each group had 34 cases. Patients in the control group were po administered with Agomelatine Tablets, 25-50 mg/d. Patients in the treatment group were po administered with Shugan Jieyu Capsules on the basis of the control group, 2 grains/time, twice daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the HAMD scores, HAMA scores and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 79.41% and 91.18%, respectively, and there were differences between two groups (P<0.05). After treatment, the HAMD and HAMA scores in two groups were significantly decreased, and there were differences in the same group (P<0.05). And the HAMD and HAMA scores in the treatment group were significantly lower than that in the control group, with significant difference between two groups (P<0.05). During the treatment, the incidence of adverse reactions in the treatment was 20.58%, which was significantly lower than 29.41% in the control group, with significant difference between two groups (P<0.05). Conclusion Shugan Jieyu Capsules combined with aggameline can effectively eliminate the patients' negative emotions and improve the quality of life in treatment of depression after cerebral infarction, which has a certain clinical application value.